Jade Biosciences Inc

JBIO remains in a Stage 2 advancing phase within its long-term uptrend, supported by Lockout Rally and Higher Highs & Higher Lows patterns. However, price is currently slipping below the short-term EMAs and the rising 50 DMA, showing sideways indecision and neutral momentum. With RSI and Options Score in mid-range and no clear exhaustion or breakout, execution readiness remains neutral, so buy-side engagement is deferred. Watch for a pullback into the EMAs or 50 DMA and subsequent acceptance before initiating new long positions.

• ↑Stock surged 69% over last 30 days, breaking above its 50-day moving average.
• ↑10 Wall Street analysts rate JBIO “Buy,” led by a $45 UBS price target.
• ↓Negative profitability and low earnings yield question cash-flow potential.